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Abstract 
Influence on diabetes mellitus type 2 on manifestation of anxiety in patients with myocardial 
revascularization has been studied. Three groups of patients were selected: patients with coronary artery 
bypass grafting; patients with stenting of coronary arteries; patients who received drug therapy. The 
research has shown that diabetes increases the risk for development of superficial wound infections, renal 
insufficiency after coronary artery bypass grafting, however patients with diabetes do not obligatory have 
the increased risk for development of severe complications and mortality after the surgery. 
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Introduction 
Ischemic heart disease (IHD) and diabetes mellitus (DM) type 2 are widespread pathologies 
which frequently combine and potentiate each other. Diabetes mellitus is the main factor in 
development of cardio-vascular diseases (CVD), and the patients who suffer from circulatory 
system diseases are more prone to diabetes [1]. 
At present the active implementation of surgical methods of treating patients with IHD, 
particularly patients with myocardial infarction (MI) with unstable angina pectoris is taking 
place in Ukraine [2].+ 
The presence of DM in patients with surgical restore of cardiac blood flow is a factor in 
development of unfavorable cardiologic and psychosomatic conditions. Insulin-dependent 
diabetes mellitus as well as insulin-independent diabetes are potential factors in the 
development of myocardial infarction and heart failure in patients with ischemic heart disease 
who survived cardio-surgical interventions [3]. 
Although a peripheral vascular disease does not affect early results of coronary artery bypass 
grafting, it has been proven that it is an independent predictor for a negative long-term survival 
among patients with myocardial revascularization [4]. 
The increased risk for cardio-vascular complications has also been associated with emotional 
disorders which are explained by behavioral and biological mechanisms [5]. The carried out 
biological examinations show that negative psychological conditions are connected with a 
higher body mass index, hypertonia, hypercholesterolemia and diabetes [6]. 
Anxiety symptoms are associated with the increased risk for ischemic heart disease, both in 
combination with depression disorders and independent of it [7]. 
Ukrainian researches have proven that the patients with DM 2 type with anxiety-depressive 
disorders have the diseases which are accompanied by more frequent appearance of 
atherosclerotic damages, including joint damage from different areas [8]. The course of the 
IHD, comorbid with the metabolic syndrome, is associated with a higher level of anxiety and 
depression, which correlates with such components of the metabolic syndrome as abdominal 
obesity, dyslipidemia and hyperglycemia [9]. 
A sufficient number of researches both in Ukraine and abroad have been focused on studies 
associated with IHD risk factors and comorbid pathologies [5, 6, 8-10]. At that the long-term 
estimation of the anxiety level in patients with IHD who had myocardial revascularization and 
its connection with the presence of DM 2 type have been insufficiently studied which enabled 
us to carry out the present research. 
The purpose of the research is to study the influence of diabetes mellitus type 2 on 
manifestations of anxiety throughout a year in patients with surgical and conservative methods 
of IHD treatment. 
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Materials and methods: 215 patients with IHD (165 males 
and 50 females) who underwent treatment in departments of 
cardiology, intervention cardiology, and cardio-surgery in SE 
“Dnipropetrovsk Regional Clinical Center of Cardiology and 
Cardiac Surgery of DRC” from 2010 to 2016 were included in 
the study. The age of the patients ranged from 39 to 82 years 
old, the average age was 59.81±0.66 (9.61) years – М±m 
(SD).  
Three groups of patients have been studied: I group (61 
patients) – patients who had coronary artery bypass grafting 
(CABG); II group (85 patients) – patients who had stenting of 
coronary arteries (SCA) and III group (69 patients) – patients 
who received drug therapy. Depending on the presence or 
absence of diabetes mellitus 2 type, the patients in the groups 
were distributed to subgroups: subgroup “a” – patients with 
DM 2 type; subgroup “b” – patients without DM 2 type.  
During the primary hospitalization, one month and one year 
after the received treatment, the level of personal and reactive 
(situational) anxiety of the patients was evaluated by 
questionnaires of Ch. Spilberger in the Russian edition – Y.L. 
Khanina. The scales of reactivity and personal anxiety (STAI 
– State-Trait Anxiety Inventory) consist of 40 questions-
opinions, from them 1 - 20 are designed to determine the level 
of reactive anxiety and 21 - 40 – to determine the level of 
personal anxiety. To each question there are 4 possible 
options to answer. The total indicator by each scale can be 
within the range 20 – 80 points. According to the 
methodology, the determination of a reactive and personal 
anxiety is carried out separately. The level of anxiety equal or 
less than 30 points is considered as low, from 31 to 45 points 
– moderate (middle), from 46 points and more – high [11].  
The analysis of the research results was carried out using 
descriptive and analytical biostatistics methods in accordance 
with the type of feature and determined type of character of 
distribution of quantitative variables with the help of the 
software STATISTICA 6.1 (StatSoftInc., serial number 
AGAR909E415822FA). 
The check of the normal distribution hypothesis among the 
studied quantitative features was held by Shapiro-Wilk 
criterion, evenness of variance – by Fisher test. Depending on 
the results of the check, parametrical and non-parametrical 
methods of statistics were used. In case of a normal 
distribution of clinical signs, the descriptive statistics included 
arithmetical mean (М), its standard deviation (SD), and 
standard error of estimate (m). In case of distribution different 
from normal – median (Ме) and interquartile range (25%; 
75%). Respectively the estimation of significance of 
discrepancies in indicators: by Student’s t-test for unbundled 
statistical sampling considering homo- and heteroscedasticity 
of dispersion and Student's t-test for the related samples or 
Mann-Whitney U-test (U) and Wilcoxon test (W) 
correspondingly відповідно. Determination of reliability in 
the discrepancy of qualitative parameters which were 
described in the form of relative indicators (%) was carried 
out using Pearson Chi-Square Test (χ2). For multiple 
comparison by parametric (ANOVA) and not-parametric 
Kruskal-Wallis one-way analysis of variance were carried out. 
Multiple comparisons were made considering Scheffe's 
method. 
The presence and interconnection density between the studied 
parameters were determined by the results of the correlation 
analysis considering Spearman's rank correlation coefficient 
(ρ). Critical value for statistical significance (p) for all types 
of analysis were taken as <5% (р<0.05). 
 
Results and discussions: The frequency of the studied patient 
with IHD and diabetes mellitus 2 type was on average 44.19% 
from the total sample. Though indicators ranged between 
34.43% in the I studied group and 45.88% – in the II and 
50.72% – in the III, there were no statistically significant 
differences by the presence of diabetes (р=0.188), which 
made possible to compare correctly subgroups by other 
indexes (Table 1). 
There were no statistically significant differences in the 
studied groups and subgroups by age and gender structure (in 
all subgroups most of the subgroup were men); level of 
systolic blood pressure (SBP). 
Subgroup 1-а was different from subgroup 1-b by indexes of 
diastolic blood pressure (DBP), which was lower in the 
subgroup of patients with coronary artery bypass graft without 
diabetes mellitus (р<0.05). 
Differences between groups were determined by the heart rate 
(HR, per 1 minute), which was the highest in the II group 76.0 
(68.0; 86.0) – Me (25%; 75%) and they were significantly 
different from indices in I and III groups (р=0.022 and 
р=0.001 respectively). There were no differences by HR in 
subgroups of one group (р>0.05). 
 
Table 1: General characteristics of the subgroups of patients with IHD 
 
Characteristics 
I group CABG (n=61) II group SKA (n=85) III group – drug treatment (n=69) 
1-а with DM 1-b without DM 2-а with DM 2-b without DM 3-а with DM 3-b without DM 
Number of patients,  
n (%) 
21 (9.77) 40 (18.6) 39 (18.14) 46 (21.4) 35 (16.28) 34 (15.81) 
Males, n (%) 17 (80.95) 36 (90) 30 (76.92) 37 (80.43) 21 (60) 24 (70.59) 
Females, n (%) 4 (19.05) 4 (10) 9 (23.08) 9 (19.57) 14 (40) 10 (29.41) 
Age, years М±m (SD) 59.86±2.06 (9.46) 57.95±1.3 (8.2) 60.95±1.45 (9.03) 59.26±1.62 (11) 60.79±1.3 (7.59) 60.41±2.02 (11.76) 
BMI, kg/m2 М±m (SD) 31.26±0.71 (3.25) 29.35±0,52 (3.32)* 31.07±0.78 (4.87) 28.37±0.47 (3.21)* 31.74±0.84 (4.99) 29.58±1.15 (6.71) 
SBP, mm Hg; Me  
(25%; 75%) 
130 (130; 140) 130 (120; 150) 140 (130; 160) 132.5 (120; 150) 140 (130; 150) 130 (130; 147,5) 
DBP, mm Hg; Me  
(25%; 75%) 
90 (80; 90) 80 (80; 90)* 80 (80; 90) 80 (80; 90) 87.5 (80; 90) 80.5 (80; 90) 
HR per 1 min. Me  
(25%; 75%) 
68 (67.5; 80) 69 (68; 76) 78 (72; 87) 72.5 (68; 80) 70 (68; 76) 68 (64; 73) 
6-minute walk test,  
m; Me (25%; 75%) 
200 (150; 350) 250 (150; 400) 175 (150; 200) 250 (200; 300)* 250 (200; 300) 350 (300; 450)* 
Glucose, mmol/l 
Me (25%;75%) 
7.5 (6.3; 9.7) 4.7 (4; 4.9)* 7.2 (6.1; 9.3) 4.25 (4; 5)* 8.4 (6.4; 11.5) 4.4 (3.9; 4.8)* 
Note * – differences between subgroups “a” and “b” at the level of statistical significance р<0.05 
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Between groups with different treatment approaches no 
differences by body mass index (BMI) were revealed. At the 
same time statistically significant differences between 
subgroups I and II groups with revascularization of 
myocardium and BMI were revealed of, the former in the 
patients with diabetes mellitus type 2 was higher than that in 
the patients without diabetes (р=0.036 and р=0.003 
respectively). In the group with drug treatment, patients with 
DM had on average higher BMI but without statistically 
significant differences (р>0.05). 
By the distance of the 6-minute walk test the highest indicator 
was revealed in the group with drug treatment without 
diabetes mellitus (р<0.05 compared with the corresponding 
subgroup with DM type 2). Moreover diabetes influenced the 
functional condition of the patients in the group with stenting 
of the coronary arteries; in the latter the increase in the 
distance of the 6-minte test in patients without DM was 
observed. Nonetheless the same trend without statistically 
significant differences was determined in the CABG group. 
By the level of glucose all subgroups without diabetes 
mellitus were statistically different (р<0.05) from the 
subgroup “a” with DM, there the level of glucose was 
significantly higher. 
The essential characteristic of emotional disorders in patients 
with IHD is the presence and severity of expressing anxiety. 
The determination of anxiety (situational) and features of 
anxiety in the examined patients which was carried out using 
the Scales of Spielberg-Khanina (Fig. 1) revealed that the 
level of anxiety of patients with diabetes mellitus is higher 
(45.00±1.53 (8.25) points in case of reactive anxiety, 
56.48±1.42 (7.66) points – in personal) in comparison with 
patients with IHD without DM (40.90±0.82 (8.45) points in 
case of reactive anxiety, 54.01±0.70 (7.23) points – in 
personal), for situational anxiety with statistically significant 
difference (р<0.05). 
During the analysis of the level of anxiety in the studied 
groups depending on the level of presence of DM (Table 2), it 
was revealed that the level of anxiety in patient with CABG 
did not depend on the course of diabetes at the initial stage of 
treatment and in a short-term period after it, however, the 
level of both personal and reactive anxiety in the subgroups 
with DM was higher without statistically significant 
differences. In the long-term period one year after the surgery, 
patients of 1-a subgroup with diabetes mellitus showed 
reliably higher (р<0.05) indexes of both personal (46.19±1.21 
versus 41.7±1.15), and reactive (35±1.36 versus 29.83±0.9) 
anxiety, which can be explained by the influence of 
manifestation of diabetes mellitus on psychological-emotional 
condition of the patients. 
 
 
 
Fig 1: Average level of personal and reactive anxiety in the studied 
patients with IHD depending on the presence of diabetes mellitus 
type 2 (М±m, points) 
 
In the group with stenting of the coronary arteries and in 
patients with drug treatment at the initial stage of the 
examination, the level of both personal and reactive anxiety in 
patients with diabetes mellitus was higher. In groups with 
myocardial revascularization the anxiety gradually decreased 
in dynamics during a year, unlike patients with drug treatment 
both in groups with IHD accompanied by DM and in 
comparison groups. 
 
Table 2: Average indexes of anxiety in subgroups of the studied patients with IHD at different stages of treatment 
 
Level of 
anxiety 
М±m (SD) 
Group 1 CABG (n=61) Group 2 SCA (n=85) Group 3 Drug treatment (n=69) 
1-а with DM 
(n=21) 
1-b without DM 
(n=40) 
2-а with DM 
(n=39) 
2-b without DM 
(n=46) 
3-а with DM 
(n=35) 
3-b without DM 
(n=34) 
Personal anxiety 
Visit 1 50.95±0.95 (4.36) 49.93±0.86 (5.44) 61.33±0.66 (4.1) 52.57±0.93 (6.31)* 61.54±0.26 (1.52) 59.41±0.95 (5.54)* 
Visit 2 48.95±1.14 (5.22) 46.7±0.8 (5.08) 45.18±0.91 (5.71) 47.26±0.88 (5.94) 62.69±0.18 (1.05) 60.47±0.99 (5.75)* 
Visit 3 46.19±1.21 (5.56) 41.7±1.15 (7.27)* 35.21±0.67 (4.21) 43.13±1.22 (8.29)* 63.49±0.4 (2.36) 61.74±0.98 (5.71) 
Discrepancies 
in dynamics 
р2-1=0.166 
р3-2=0.068 
р3-1=0.005 
р2-1=0.005 
р3-2<0.001 
р3-1<0.001 
р2-1<0.001 
р3-2<0.001 
р3-1<0.001 
р2-1<0.001 
р3-2<0.001 
р3-1<0.001 
р2-1=0.002 
р3-2=0.069 
р3-1=0.001 
р2-1=0.375 
р3-2=0.260 
р3-1=0.039 
Reactive anxiety 
Visit 1 39.05±0.97 (4.44) 38.25±0.87 (5.48) 48.92±0.72 (4.51) 39.11±1.07 (7.23)* 52.03±0.13 (0.75) 45.38±1.64 (9.59)* 
Visit 2 36.9±1.43 (6.53) 36.45±0.84 (5.33) 38.15±0.56 (3.47) 36.04±0.95 (6.45) 54.17±0.14 (0.82) 46.53±1.48 (8.62)* 
Visit 3 35±1.36 (6.24) 29.83±0.9 (5.72)* 27.62±0.53 (3.33) 31.96±1.24 (8.44)* 52.74±0.14 (0.85) 46.21±1.58 (9.2)* 
Discrepancies 
in dynamics 
р2-1=0.108 
р3-2=0.140 
р3-1=0.023 
р2-1=0.117 
р3-2<0.001 
р3-1<0.001 
р2-1<0.001 
р3-2<0.001 
р3-1<0.001 
р2-1=0.001 
р3-2=0.001 
р3-1<0.001 
р2-1<0.001 
р3-2<0.001 
р3-1=0.001 
р2-1=0.420 
р3-2=0.808 
р3-1=0.665 
Notes. Discrepancies in dynamics: 
р2-1 – between 2nd and 1st visits; 
р3-2 – between 3rd and 2nd visits; 
р3-1 – between 3rd and 1st visits; 
* – discrepancies between subgroups “a” and “b” at the level of statistical significance р<0,05 
 
 
With DM 
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The influence of diabetes mellitus on the increase in the level 
of both personal and reactive anxiety can be observed in 
patients with a surgical recovery of cardiac blood supply 
(both in case of CABG and stenting of the coronary arteries) 
at the initial stage of treatment and one year after the 
intervention, in patients with drug treatment – during the 
whole period of examination. At first examination which 
coincided with the assignment of the corresponding method of 
treatment (surgical or conservative) reactive anxiety as a 
reaction of a person to a stressful situation was the highest in 
IHD patients with diabetes mellitus who were prescribed drug 
treatment – 52.03±0.13 (0.75) points. One month later this 
subgroup showed the increase in the level of reactive anxiety 
(р<0,001), after one year it decreased (р=0.001), not reaching 
the initial level. In the subgroup of IHD patients without 
diabetes mellitus, who were prescribed conservative 
treatment, reactive anxiety in all stages of observation was 
significantly lower (р<0.05) and remained almost stable in 
dynamics (р>0.05). 
The increased personal anxiety, which is considered as a 
relatively stable individual trait of a personality, is higher than 
the level of reactive anxiety in all studied subgroups. If a 
personal anxiety is a stable individual characteristic, the 
condition of the reactive anxiety can be rather dynamic both 
by time and the degree of expression [4]. 
Reactive (situational) anxiety – is a condition characterized by 
the level of a person’s anxiety which develops in a certain 
stressful situation. If at the beginning of the treatment and in a 
short-term period or the surgical intervention if needed, the 
determination of the treatment approach is that stressful 
situation then one year later among stressful factors 
concomitant, comorbid pathologies are essential, they degrade 
the quality of life, in particular diabetes mellitus. This 
conclusion is confirmed by the results of the estimations in 
group 3 in which 1 year after basic drug treatment a high level 
of reactive anxiety (45 points and higher) was observed in all 
patients with DM unlike the patients with isolated IHD (Fig. 
2). 
 
 
 
Fig 2: Distribution by the expression of reactive anxiety level in 
subgroups of patients with IHD 1 year after the beginning of 
treatment, n (%) 
 
According to the rank correlation analysis it was determined 
that the presence of diabetes mellitus type 2 correlates in 
patients with IHD, who require myocardial vascularization, 
with BMI (Spearman's rank correlation coefficient – ρ=0.29; 
р=0.001); with SBP (ρ=0.15; р=0.034); with DBP (ρ=0.31; 
р=0.018); strong connection with the level of glucose 
(ρ=0.76; р<0.001) and inverse relationship with the results of 
6-minute walk test (ρ=-0.33; р<0.001). 
The presence or absence of DM in patients influences the 
level of reactive anxiety of the studied patients, which is 
significantly manifested at the primary level of treatment – 
statistically significant correlation connection was determined 
between the level of reactive anxiety and presence of DM 
(ρ=0.19; р=0.022), which is most manifested in the group 
which requires stenting of the coronary arteries (ρ=0.50; 
р<0.001). 
 
Conclusions: As a result of the carried out research we can 
conclude that the patients who have severe forms of ischemic 
heart disease and require recovery cardiac blood supply with 
diabetes mellitus type 2 represent a group with a higher risk 
due to major vascular disorders. It has been confirmed by the 
direct connection between DM and the increased level of SBP 
(ρ=0.15; р=0.034) and DBP (ρ=0.31; р=0.018), inverse – 
with the distance of a 6-minute walk test (ρ=-0.33; р<0.001). 
The course of IHD, comorbid with DM type 2 is associated 
with a higher level of reactive anxiety (ρ=0.19; р=0.022). 
Diabetes mellitus considering a complicated regime of control 
and treatment as well as multiple somatic manifestations, 
acute and chronic complications, provides the increased 
influence on the emotional condition of patients, which is 
reflected in the increased level of anxiety, especially reactive 
anxiety which is the highest and provides no positive 
dynamics in the long-term prospect in the group of patients 
who are prescribed conservative treatment. 
The presence of DM type 2 worsens the quality of life of 
patients with IHD due to the increased level of anxiety both in 
short-term and long-term periods therefore such patients 
should be rendered utmost care and thorough medical control 
and examination. 
Prospects for further research can be considered in finding out 
whether drug treatment of anxiety disorders influences the 
psychological-emotional condition of patients with 
myocardial vascularization and the condition of their cardio-
vascular system. 
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